Migraine treatment

Oct 05, 2026

Summary Migraine affects approximately one in seven people globally and remains underdiagnosed and undertreated. Migraine care has shifted from repurposed drugs such as antihypertensives, antidepressants, and anticonvulsants toward mechanism-specific therapies targeting the CGRP pathway. Unlike triptans, ...

Sep 30, 2026

Migraine has always been treated as a pill problem. Take something, wait, and hope it works before the pain peaks. Digital migraine treatment devices are quietly upending that assumption, offering people a way to interrupt an attack or prevent one from building in the first place, using electrical, magnetic, or sen...

Aug 12, 2025

FDA Expands Teva’s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6–...

May 20, 2025

Incyte’s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer The FDA approved ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The approval incl...

Jun 09, 2021

Migraine is a medical condition characterized by recurrent headaches that can last from 4 to 72 hours and often results in a wide range of symptoms. It is mainly associated with a painful headache, however, the affected person may experience nausea, vomiting, disturbed vision, sensitivity to light, sound, and smell...

Oct 07, 2019

The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability. According to the Migraine Trust Organization, Migraine is ranked as the 7th most disabling disease in the world (a cause for a loss of 2.9% of all years of life lost to disability/YLDs). The ...